… ts at risk of developing an intestinal obstruction. Tablet residues from slow release formulations of the product may pass into the patient's stools; however, this finding has no clinical relevance.
This medicine contains less than 1 mmol sodium (23 mg) per capsule, that is to say essentially 'sodium-free'.
Identical in both labels. Surrounding text shown from Napp Pharmaceuticals Limited.
… ith preexisting bronchial hyper-reactivity. Cases have also been reported after dose increase. Patients should be monitored for signs and symptoms of respiratory impairment during diltiazem therapy.
This medicine contains less than 1 mmol sodium (23 mg) per capsule that is to say essentially 'sodium-free'.
Caution should be exercised when direct oral anticoagulants (DOACs) are co-administered with Diltiazem which is a moderate CYP3A4 and a weak P-gp inhibitor, particularly in patients at high risk of …
Identical in both labels. Surrounding text shown from SANOFI.
… when direct oral anticoagulants (DOACs) are co-administered with Diltiazem which is a moderate CYP3A4 and a weak P-gp inhibitor, particularly in patients at high risk of bleeding (see section 4.5).
This medicine contains less than 1 mmol sodium (23mg) per capsule, that is to say essentially 'sodium-free'.